Morniflumate is an NSAID derived from niflumic acid used in the symptomatic treatment of inflammatory conditions of the airways, ENT, and the urogenital and osteoarticular systems. Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties.
- Mechanism
- Curator reviewed · 4 references
The primary mechanism of niflumic acid and its ester is action is inhibition of enzymes involved in the synthesis of inflammatory prostaglandins. This medication inhibits cyclooxygenase and 5-lipoxygenase pathways, which lead to fever and inflammation.
Niflumic acid, a calcium-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of inflammatory conditions. Niflumic acid does directly inhibit calcium channels or activate potassium channels. Niflumic acid selectively reduces noradrenaline- and 5-HT-induced pressor responses by inhibiting a mechanism which leads to the opening of voltage-gated calcium channels. Niflumic acid (NFA) produces biphasic behavior on human CLC-K channels that suggests the presence of two functionally different binding sites: an activating site and a blocking site.
- Primary indication
- Morniflumate is indicated for the treatment of inflammatory conditions affecting the airways, ENT system, urogenital tract and bone and joint systems in adults.Curator reviewed · 14 structured indications
- Formula / weight
- C19H20F3N3O3 · 395.382 g/mol (avg)
- Code names
- UP 164
Resolves to
LDXSPUSKBDTEKA-UHFFFAOYSA-NSMILESFC(F)(F)C1=CC(NC2=C(C=CC=N2)C(=O)OCCN2CCOCC2)=CC=C1What you can answer from here — as of March 06, 2025
Which drugs share a target with Morniflumate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account